Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AAHI-SC2

Vaccine (mRNA vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by ImmunityBio

Phase 1/2 Most advanced trial (none active)
IBRX Developer
1 Registered trials

What is AAHI-SC2?

AAHI-SC2 is a self-amplifying RNA vaccine encoding the SARS-CoV-2 spike protein, delivered via nanostructured lipid carrier. It is studied for COVID-19 prevention.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (mRNA vaccine)
Targets
SARS-CoV-2 spike protein (antigen)
Mechanism
Immune activation, directed at SARS-CoV-2 spike protein
Pathways
immune_activation
Therapy area
Infectious disease
Developer
ImmunityBio, Inc. (IBRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05370040 Phase 1/2 COVID-19 Terminated IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19

More from ImmunityBio

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind AAHI-SC2

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.